Compare Stocks: INBX, ERAS, TVTX, and DNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$105.84 -5.1%	$103.59	$22.81 ▼ $117.88	$5.79B	1.22	690,947 shs	376,227 shs
ERAS Erasca	$18.03 -7.5%	$18.20	$1.33 ▼ $24.28	$6.31B	0.66	3.16 million shs	2.89 million shs
INBX Inhibrx Biosciences	$123.41 -0.4%	$94.29	$26.19 ▼ $155.29	$1.82B	3.51	264,892 shs	241,481 shs
TVTX Travere Therapeutics	$65.67 -2.7%	$59.34	$17.27 ▼ $67.85	$6.19B	1.12	1.72 million shs	808,213 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	-4.73%	-6.04%	+13.79%	+336.63%
ERAS Erasca	0.00%	+2.27%	-3.48%	+40.42%	+1,041.14%
INBX Inhibrx Biosciences	0.00%	+19.09%	+45.65%	+18.72%	+350.40%
TVTX Travere Therapeutics	0.00%	-0.06%	+14.65%	+39.19%	+276.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$105.84 -5.1%	$103.59	$22.81 ▼ $117.88	$5.79B	1.22	690,947 shs	376,227 shs
ERAS Erasca	$18.03 -7.5%	$18.20	$1.33 ▼ $24.28	$6.31B	0.66	3.16 million shs	2.89 million shs
INBX Inhibrx Biosciences	$123.41 -0.4%	$94.29	$26.19 ▼ $155.29	$1.82B	3.51	264,892 shs	241,481 shs
TVTX Travere Therapeutics	$65.67 -2.7%	$59.34	$17.27 ▼ $67.85	$6.19B	1.12	1.72 million shs	808,213 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	-4.73%	-6.04%	+13.79%	+336.63%
ERAS Erasca	0.00%	+2.27%	-3.48%	+40.42%	+1,041.14%
INBX Inhibrx Biosciences	0.00%	+19.09%	+45.65%	+18.72%	+350.40%
TVTX Travere Therapeutics	0.00%	-0.06%	+14.65%	+39.19%	+276.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$124.27	17.42% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	22.52% Upside
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	60.04% Upside
TVTX Travere Therapeutics	2.69	Moderate Buy	$61.67	-6.10% Downside

Current Analyst Ratings Breakdown

Latest INBX, ERAS, TVTX, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/24/2026	INBX Inhibrx Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$245.00
8/17/2026	TVTX Travere Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	ERAS Erasca	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/13/2026	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $21.00
8/12/2026	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $22.00
8/10/2026	TVTX Travere Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$78.00
8/6/2026	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$61.00 ➝ $75.00
8/6/2026	TVTX Travere Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$62.00 ➝ $70.00
8/6/2026	DNTH Dianthus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $128.00
8/6/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $158.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$1.90M	3,038.79	N/A	N/A	$21.44 per share	4.94
ERAS Erasca	N/A	N/A	N/A	N/A	$1.03 per share	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	($3.60) per share	N/A
TVTX Travere Therapeutics	$591.33M	10.47	$0.36 per share	181.34	$0.26 per share	252.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
TVTX Travere Therapeutics	-$25.55M	-$0.46	N/A	24.97	N/A	-7.35%	-55.15%	-6.88%	10/29/2026 (Estimated)

Latest INBX, ERAS, TVTX, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
8/4/2026	Q2 2026	TVTX Travere Therapeutics	-$0.1347	-$0.10	+$0.0347	-$0.37	$157.27 million	$169.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	26.10	26.10
ERAS Erasca	N/A	8.29	8.29
INBX Inhibrx Biosciences	12.58	5.07	5.07
TVTX Travere Therapeutics	24.58	4.05	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
ERAS Erasca	67.78%
INBX Inhibrx Biosciences	82.46%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	3.02%
ERAS Erasca	14.20%
INBX Inhibrx Biosciences	18.26%
TVTX Travere Therapeutics	4.44%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	80	54.67 million	53.02 million	Optionable
ERAS Erasca	120	349.76 million	300.10 million	Optionable
INBX Inhibrx Biosciences	166	14.72 million	12.03 million	Optionable
TVTX Travere Therapeutics	460	94.26 million	90.08 million	Optionable

INBX, ERAS, TVTX, and DNTH Headlines

Recent News About These Companies

Jefferies Financial Group Inc. Takes Position in Travere Therapeutics, Inc. $TVTX

August 30 at 5:20 AM | marketbeat.com

Legal & General Group Plc Makes New Investment in Travere Therapeutics, Inc. $TVTX

August 30 at 4:57 AM | marketbeat.com

220,611 Shares in Travere Therapeutics, Inc. $TVTX Bought by Hsbc Holdings PLC

August 29 at 5:36 AM | marketbeat.com

167,525 Shares in Travere Therapeutics, Inc. $TVTX Bought by Palo Alto Investors LP

August 28 at 6:39 AM | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month High - Time to Buy?

August 27 at 3:20 AM | americanbankingnews.com

Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Still a Buy?

August 27 at 3:20 AM | marketbeat.com

Artia Global Partners LP Buys New Shares in Travere Therapeutics, Inc. $TVTX

August 27 at 3:13 AM | marketbeat.com

11,324,191 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Jupiter Topco LLC

August 26, 2026 | marketbeat.com

Elmind Capital LP Invests $16.62 Billion in Travere Therapeutics, Inc. $TVTX

August 26, 2026 | marketbeat.com

Deutsche Bank AG Purchases New Stake in Travere Therapeutics, Inc. $TVTX

August 23, 2026 | marketbeat.com

Travere Therapeutics Signals Strong Growth in Earnings Call

August 22, 2026 | theglobeandmail.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 22, 2026 | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Analysts

August 22, 2026 | marketbeat.com

IBD stock of the day, Travere Therapeutics, tests another breakout. Can the stock get any 'sweeter?'

August 21, 2026 | msn.com

Travere Therapeutics (NASDAQ:TVTX) Sets New 52-Week High - Should You Buy?

August 21, 2026 | marketbeat.com

Lisanti Capital Growth LLC Makes New $6.76 Million Investment in Travere Therapeutics, Inc. $TVTX

August 20, 2026 | marketbeat.com

Travere Therapeutics: Valuation Suggests A Buy

August 19, 2026 | seekingalpha.com

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline

August 18, 2026 | marketbeat.com

97,573 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Rice Hall James & Associates LLC

August 18, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $2.10 Million in Travere Therapeutics, Inc. $TVTX

August 17, 2026 | marketbeat.com

S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX

August 16, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX, ERAS, TVTX, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$105.84 -5.70 (-5.11%)

As of 08/28/2026 04:00 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Erasca NASDAQ:ERAS

$18.03 -1.46 (-7.49%)

As of 08/28/2026 04:00 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Inhibrx Biosciences NASDAQ:INBX

$123.41 -0.52 (-0.42%)

As of 08/28/2026 04:00 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Travere Therapeutics NASDAQ:TVTX

$65.67 -1.85 (-2.74%)

As of 08/28/2026 04:00 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INBX, ERAS, TVTX, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INBX, ERAS, TVTX, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INBX, ERAS, TVTX, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX, ERAS, TVTX, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Inhibrx Biosciences NASDAQ:INBX

Travere Therapeutics NASDAQ:TVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INBX, ERAS, TVTX, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INBX, ERAS, TVTX, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INBX, ERAS, TVTX, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX, ERAS, TVTX, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Inhibrx Biosciences NASDAQ:INBX

Travere Therapeutics NASDAQ:TVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools